Navigation Links
Sinovac Reports Unaudited Second Quarter Financial Results
Date:8/14/2014

and safe. We expect these initiatives to meaningfully contribute to our performance as market conditions improve." Mr. Yin concluded.

Second Quarter 2014 Business HighlightsSales UpdatePublic Tenders Sinovac has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately RMB 16 million. The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The Company expects to begin delivery in the coming months.

Additionally, Sinovac has also been selected by the Beijing Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014. The Company expects to begin delivery in the third quarter of 2014.

International Sales to Mexico Sinovac obtained its commercialization license for Anflu in Mexico late last year. In early July, the Company delivered its first order of 150,000 doses of Anflu to Mexico, as it continues its efforts in international market expansions.

R&D UpdatePPV The Company received clinical trial approval for its PPV in May. Sinovac has selected a site for the clinical trial and its draft proposal is currently under expert review. The Company expects clinical trials to begin by the end of 2014, following approval by an ethics committee.

Other Operation UpdatesGovernment Grant In April, Sinovac received approval for a RMB 60 million government grant from China's Ministry of Finance, National Development and Reform Commission, Ministry of Industry and Information Technology, and National Health and Family Planning Commission for construction of the Company's dedicated EV71 vaccine production facility. Sinovac received the first RMB 20 million of the grant in July. The remainder will be provided once construction and approval criteria are met.

VAT Rat
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
2. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
5. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
6. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
7. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
8. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
9. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center
10. GenVec Reports Second Quarter 2014 Financial Results
11. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider ... with a team of researchers from Yale University’s School ... Collaborative to provide electronic questionnaire data collection through use ... started in May, aims to evaluate the impact of ... to and participation in urban agriculture to impact their ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/20/2014)... 2014 The report “Pharmacy Automation ... Packaging and Labeling Systems, Table-top Counters) by End-user ... Forecasts & Trends to 2019” analyzes and studies ... North America, Europe, Asia-Pacific, and the Rest of ... and 30 figures spread through 300 pages and ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SWX: ORIDN) today ... leading global medical device and service company.,With ... technology in its new, compact and ultra-lightweight ... the importance of monitoring CO2, has,decided to ...
... $2.0 Million -, MONTVALE, N.J., Aug. 26 ... it has secured,$2.0 million through the sale of approximately ... under its June 2007 equity financing agreement,with an investment ... Pharmaceuticals exercised its option to complete the third,and final ...
... Calif., Aug. 26 The 2008 European ... presented to,Israel-based Vascular Biogenics Ltd. for developing ... has facilitated novel advancements,in gene expression-based treatments ... VTS(TM) platform is a potent and flexible ...
Cached Biology Technology:Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 2Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 3Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 4Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 2Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 3Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 2Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 3
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... Invasive species plants, animals, and microbes introduced to regions ... tag of $1.4 trillion dollars . They are responsible for ... and an uptick in infectious diseases. Not all non-native ... the last several decades teasing apart the conditions that set ...
... 2012 In forested regions of the nation, natural regeneration ... of maintaining the desired tree species. , A study by ... and Urban Greening showed that on average, 1 in ... from natural regeneration. However, for newly established, young trees in ...
... , When you take a dip in the ocean, nuclear fuel ... Earths oceans in trace amounts of just 3 parts per billion, ... billion tons of uranium enough to potentially fuel the worlds ... the ocean as a uranium source since the 1960s, but previous ...
Cached Biology News:Losing stream in our battle to predict and prevent invasive species 2Losing stream in our battle to predict and prevent invasive species 3Natural regeneration building urban forests, altering species composition 2Natural regeneration building urban forests, altering species composition 3
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... Gel Loading Buffer contains a precipitant to ... and a tracking dye to allow the user ... Components ReddyRun™: ABgene ® s ... with the same buffer composition used in ReddyRun™ ...
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,381-3) or ...
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
Biology Products: